Melbourne, Florida, USA – Alertgy, an innovative healthcare biotech startup based in Melbourne, FL, is pleased to announce that the company has won the top prize at the International 42PLUS1 DxPx Conference EU 2021 Competition recently held in Dusseldorf, Germany. The competition saw 237 entries from companies across the world. Alertgy was awarded the top prize from amongst 8 other global finalists. Prior to this award, Alertgy secured top spot in DxPx’ North American competition.
42PLUS1 is Europe’s highest prized pitch award dedicated to the diagnostics, precision medicine and life science tools industry. 42PLUS1 is part of the DxPx Conference and is powered by Silversky LifeSciences.
Speaking on the occasion, Marc Rippen, Alertgy’s CEO and Founder said, “This global recognition and monetary prize will allow our company to accelerate the speed of clinical trials in the US and Europe, develop the next generation device, and hire top-level medtech talent to take us to the next level. We are extremely excited and proud of what we’ve been able to accomplish in the last 4 years and DxPx is a validation of our efforts. We are looking forward to commercializing our glucometer and helping hundreds of millions of patients worldwide afflicted with diabetes as well as the ever-growing pre-diabetic population.”
Alertgy provides Type 2 diabetics a way to non-invasively monitor their blood glucose levels on demand, provide trending information and alert them automatically if their levels are too low or high. Alertgy uses advanced materials and sensor technologies enabled by an application on a smartphone.
The company has developed an inert non-invasive sensor system that is embedded in a comfortable wrist band. Alertgy’s technology eliminates the need for implanted sensors, patches or devices that use chemical reactions or fluid transfer through the skin, clamped devices that use lasers or other intrusive measurement techniques.
“Our clients are a top priority for us and we want to make sure we provide them the latest and updated technology,” says Marc. “We will continue to invest in research and development, so that we can always offer top-class products to our users.”
With the development of a groundbreaking glucose monitoring technology, Alertgy is set to revolutionize the future of blood glucose monitoring instruments. The company has been granted a patent for their innovative and pioneering radio frequency sensor technology. As a biotech startup, this patent validates Alertgy’s state-of-the-art technology as it continues to be improved, with the ultimate goal of transforming the world of diabetes management.
Alertgy is a healthcare biotech startup that has developed a non-invasive way to measure real-time blood glucose monitoring in a wristband format – using a proprietary Deep-Gluco technology they developed. Diabetics can use this system to monitor blood sugar levels without the need to prick themselves or draw blood.
To gain access to their non-confidential company deck and other materials please contact:
Director of Marketing and Communications
2412 Irwin Street
Melbourne, FL 32901